Citigroup’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

Citigroup’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$287K	Buy	11,095 +9,968	+884%	+$256K	﹤0.01%	3815
2025 Q4	$25.9K	Buy	1,127 +1,084	+2,521%	+$18.8K	﹤0.01%	4797
2025 Q3	$160	Buy	+43	New	+$146	﹤0.01%	5779
2022 Q2	–	Sell	-10	Closed	-$1K	–	6384
2022 Q1	$1K	Hold	10	–	–	﹤0.01%	6165
2021 Q4	$1K	Hold	10	–	–	﹤0.01%	5762
2021 Q3	$1K	Hold	10	–	–	﹤0.01%	5696
2021 Q2	$1K	Buy	+10	New	+$1.36K	﹤0.01%	6032

Other funds holding DMRA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

RCP

Remedium Capital Partners Fort Lauderdale, Florida $281M AUM

Citigroup's DMRA Position: Q1 2026 in Review

Citigroup increased its Damora Therapeutics, Inc. Ordinary Shares (DMRA) stake by 884% in Q1 2026, buying an estimated $256K and bringing the position to 11,095 shares worth $287K. The position accounts for ﹤0.01% of the portfolio, ranked #3815.

Citigroup first reported a position in DMRA in Q2 2021 and has held it in 7 quarters since. 65 funds tracked by Wall St. Rank hold DMRA as of Q1 2026.

Citigroup held 11,095 shares of Damora Therapeutics, Inc. Ordinary Shares worth $287K as of Q1 2026.
Citigroup bought 9,968 Damora Therapeutics, Inc. Ordinary Shares shares in Q1 2026, an estimated $256K.
Damora Therapeutics, Inc. Ordinary Shares made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3815 holding.
Citigroup first reported a position in Damora Therapeutics, Inc. Ordinary Shares in Q2 2021 and has held it in 7 quarters since.
65 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.